Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dare Bioscience (DARE) Liabilities and Shareholders Equity (2016 - 2025)

Dare Bioscience (DARE) has disclosed Liabilities and Shareholders Equity for 11 consecutive years, with $30.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Liabilities and Shareholders Equity rose 70.27% year-over-year to $30.7 million, compared with a TTM value of $84.4 million through Sep 2025, up 11.17%, and an annual FY2024 reading of $22.1 million, up 3.85% over the prior year.
  • Liabilities and Shareholders Equity was $30.7 million for Q3 2025 at Dare Bioscience, up from $13.0 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $55.8 million in Q4 2021 and bottomed at $10.5 million in Q1 2021.
  • Average Liabilities and Shareholders Equity over 5 years is $29.7 million, with a median of $23.6 million recorded in 2024.
  • The sharpest move saw Liabilities and Shareholders Equity surged 639.1% in 2021, then tumbled 57.15% in 2024.
  • Year by year, Liabilities and Shareholders Equity stood at $55.8 million in 2021, then dropped by 21.47% to $43.8 million in 2022, then plummeted by 51.44% to $21.3 million in 2023, then grew by 3.85% to $22.1 million in 2024, then skyrocketed by 39.13% to $30.7 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for DARE at $30.7 million in Q3 2025, $13.0 million in Q2 2025, and $18.6 million in Q1 2025.